The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Palantir Technologies has raised its annual revenue forecast for the second time, signaling robust demand for its data analytics software from both government and commercial clients. This upward revision is driven by high demand for the company's AI and data platforms, particularly within the US market. Similarly, Vertex Pharmaceuticals also increased its full-year guidance, supported by strong sales performance in its specialized drug portfolio.
Sign in to access this content
Sign InPer market data, PLTR shares closed at $123.06 (close July 31, 2026), having traded between a day low of $119.62 and a high of $123.39. The simultaneous guidance hikes from growth-oriented firms like Palantir and Vertex suggest a resilient demand environment for high-end technology and biotech innovations, even as broader market conditions remain under scrutiny.
Investors are watching for PLTR to maintain levels above the $119.62 support established at the end of July. With the Federal Reserve recently holding interest rates at 3.75% as of July 29, 2026, the focus for retail traders remains on whether these raised revenue targets will translate into sustained momentum for high-growth tech stocks in the coming weeks.